Skye Bioscience, Inc. (SKYE) AI Dilution Summary

Cash was $10,064,141 at 2026-06-30, against estimated monthly burn of $2,373,891. The active funding facility is an at-the-market program with Piper Sandler & Co. It is authorised to $100,000,000, and $0 has been sold through it to date. The main dilution driver is registered capacity stated in dollars, so the same dollar amount buys more shares at a lower price.